(Q44814996)

6 December 2017

An anti-HIV strategy combining chemotherapy and therapeutic vaccination (English)

1 reference

6 December 2017

9

1 reference

6 December 2017

0 references

B Rosenwirth

1

1 reference

6 December 2017

W M Bogers

2

1 reference

6 December 2017

I G Nieuwenhuis

3

1 reference

6 December 2017

P T Haaft

4

1 reference

6 December 2017

H Niphuis

5

1 reference

6 December 2017

E M Kuhn

6

1 reference

6 December 2017

N Bischofberger

7

1 reference

6 December 2017

V Erfle

8

1 reference

6 December 2017

P Berglund

10

1 reference

6 December 2017

P Liljestrom

11

1 reference

6 December 2017

K Uberla

12

1 reference

6 December 2017

J L Heeney

13

1 reference

6 December 2017

1 August 1999

1 reference

Journal of Medical Primatology

6 December 2017

1 reference

6 December 2017

28

1 reference

6 December 2017

195-205

1 reference

6 December 2017

4-5

1 reference

Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

6 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Decay characteristics of HIV-1-infected compartments during combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: prelude to a clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0684.1999.TB00270.X

10.1111/J.1600-0684.1999.TB00270.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference